Your browser doesn't support javascript.
loading
The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research.
Wood, Libby; Cordts, Isabell; Atalaia, Antonio; Marini-Bettolo, Chiara; Maddison, Paul; Phillips, Margaret; Roberts, Mark; Rogers, Mark; Hammans, Simon; Straub, Volker; Petty, Richard; Orrell, Richard; Monckton, Darren G; Nikolenko, Nikoletta; Jimenez-Moreno, Aura Cecilia; Thompson, Rachel; Hilton-Jones, David; Turner, Chris; Lochmüller, Hanns.
Afiliación
  • Wood L; John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK. elizabeth.wood2@ncl.ac.uk.
  • Cordts I; John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Atalaia A; Department of Neurology, RWTH Aachen University, Aachen, Germany.
  • Marini-Bettolo C; John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Maddison P; John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Phillips M; Department of Neurology, Queen's Medical Centre, Nottingham, UK.
  • Roberts M; Department of Rehabilitation Medicine, Derby Teaching Hospitals NHS Foundation Trust, Derby, UK.
  • Rogers M; Department of Neurology, Salford Royal NHS Foundation Trust, Salford, UK.
  • Hammans S; Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK.
  • Straub V; Wessex Neurological Centre, University Hospital of Southampton, Southampton, UK.
  • Petty R; John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Orrell R; Department of Neurology, NHS Greater Glasgow and Clyde, Southern General Hospital, Glasgow, UK.
  • Monckton DG; Department of Neurology, Royal Free Hospital, London, UK.
  • Nikolenko N; Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, UK.
  • Jimenez-Moreno AC; John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Thompson R; John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Hilton-Jones D; John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Turner C; Department of Clinical Neurology, John Radcliffe Hospital, Oxford, UK.
  • Lochmüller H; UCL MRC Centre for Neuromuscular Diseases, Institute of Neurology, London, UK.
J Neurol ; 264(5): 979-988, 2017 May.
Article en En | MEDLINE | ID: mdl-28397002
ABSTRACT
Myotonic dystrophy type 1 (DM1) is the most frequent muscular dystrophy worldwide with complex, multi-systemic, and progressively worsening symptoms. There is currently no treatment for this inherited disorder and research can be challenging due to the rarity and variability of the disease. The UK Myotonic Dystrophy Patient Registry is a patient self-enrolling online database collecting clinical and genetic information. For this cross-sectional "snapshot" analysis, 556 patients with a confirmed diagnosis of DM1 registered between May 2012 and July 2016 were included. An almost even distribution was seen between genders and a broad range of ages was present from 8 months to 78 years, with the largest proportion between 30 and 59 years. The two most frequent symptoms were fatigue and myotonia, reported by 79 and 78% of patients, respectively. The severity of myotonia correlated with the severity of fatigue as well as mobility impairment, and dysphagia occurred mostly in patients also reporting myotonia. Men reported significantly more frequent severe myotonia, whereas severe fatigue was more frequently reported by women. Cardiac abnormalities were diagnosed in 48% of patients and more than one-third of them needed a cardiac implant. Fifteen percent of patients used a non-invasive ventilation and cataracts were removed in 26% of patients, 65% of which before the age of 50 years. The registry's primary aim was to facilitate and accelerate clinical research. However, these data also allow us to formulate questions for hypothesis-driven research that may lead to improvements in care and treatment.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sistema de Registros / Fatiga / Distrofia Miotónica Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Neurol Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sistema de Registros / Fatiga / Distrofia Miotónica Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Neurol Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido